Last reviewed · How we verify
A Phase I Trial of a Combined Regimen of Chemotherapy and 90Y-Labeled, Humanized LL2 (Anti-CD22) Antibody With Peripheral Stem Cell Rescue for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver cancer killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody plus combination chemotherapy and peripheral stem cell transplantation in treating patients who have recurrent or B-cell cancer.
Details
| Lead sponsor | Garden State Cancer Center at the Center for Molecular Medicine and Immunology |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Start date | 1997-06 |
Conditions
- Leukemia
- Lymphoma
Interventions
- filgrastim
- cisplatin
- cytarabine
- etoposide
- ifosfamide
- autologous bone marrow transplantation
- peripheral blood stem cell transplantation
- indium In 111 LL2 IgG
- yttrium Y 90 epratuzumab
Countries
United States